drugset / Trial / NCT00963053

VA111913 Dysmenorrhoea Efficacy and Safety Proof of Concept

NCT00963053 ↗

Phase 2 Completed 146 enrolled Vantia Ltd
RandomizedCrossoverTriple-blindTreatment

Summary

The purpose of the study is to investigate how effective VA111913 is at preventing menstrual pain in women with primary dysmenorrhoea.

Timeline

Start
2009-08
Primary completion
2010-09
Completion
2010-11

Drugs

EvaluationDrugModalityDoseRoute
Subject VA111913 Unknown 100 mg Oral

Indications